PMA device
MiniMed 770G System
Medtronic Minimed, Inc. · Automated Insulin Dosing Device System, Single Hormonal Control (OZP, Class III) · First FDA decision Aug 31, 2020, newest Aug 20, 2025Diabetes
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
Breakthrough-designated
Device trials
1
Naming "MiniMed 770G"
MAUDE reports
97,470
Brand "MiniMed 770G", since 2015
PubMed studies
13
Mentioning "MiniMed 770G"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing MiniMed 770G System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- MiniMed 770G SystemPMA supplement
P160017-S122 · Decided Aug 20, 2025 · 180 days after receipt · Normal 180 Day Track No User Fee
Device type: Automated insulin dosing device system, single hormonal control (OZP) · Laboratory Medicine & Pathology
- MiniMed 770G SystemBreakthroughPMA supplement
P160017-S076 · Decided Aug 31, 2020 · 304 days after receipt · Panel Track
Device type: Automated insulin dosing device system, single hormonal control (OZP) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "MiniMed 770G", any status and sponsor, newest update first.
- Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at HomePivotal-lookingCompleted
Medtronic MiniMed, Inc.Public (MDT)
NCT02748018 · 959 participants · Start May 25, 2017 · Primary completion Nov 1, 2023
Device: 670G and 770G Insulin Pump; Subject's Current Diabetes Therapy · For: Type 1 Diabetes
Sites: La Jolla, California; Palo Alto, California; Sacramento, California · 36 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "MiniMed 770G", and for the whole product code for context.
This brand
97,470 reports: 82,654 malfunction, 14,596 injury, 220 death
Whole product code OZP
911,539 reports: 781,296 malfunction, 128,965 injury, 1,268 death
Newest reports for this brand
- MiniMed 770G US System BLE Connect 3.0 mg/dLMalfunction
Medtronic Puerto Rico Operations Co.
2032227-2026-264295 · Received Oct 30, 2026 · Event dated Oct 15, 2026
Device type: Automated Insulin Dosing Device System, Single Hormonal Control (OZP)
Device problem as coded: Battery Problem; Priming Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
Medtronic Puerto Rico Operations Co.
2032227-2026-263446 · Received Oct 29, 2026 · Event dated Oct 14, 2026
Device type: Automated Insulin Dosing Device System, Single Hormonal Control (OZP)
Device problem as coded: Obstruction of Flow
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- MiniMed 770G US System BLE Connect 3.0 mg/dLMalfunction
Medtronic Puerto Rico Operations Co.
2032227-2026-263476 · Received Oct 29, 2026 · Event dated Oct 16, 2026
Device type: Automated Insulin Dosing Device System, Single Hormonal Control (OZP)
Device problem as coded: Obstruction of Flow
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- MiniMed 670G Insulin Pump, Model: MMT-1781, MMT-1782;Open, Classified
Z-2981-2026 · Started Jul 13, 2026 · Posted by FDA Aug 18, 2026
Reason given: Loaner insulin pumps may have been cleaned with chemically incompatible products that could damage the pump case or keypad, allow moisture ingress, and result in insulin over- or under-delivery, potentially causing hypoglycemia, hyperglycemia, or diabetic ketoacidosis.
Cause as FDA categorized it: Process design · Device type: Automated Insulin Dosing Device System, Single Hormonal Control (OZP)
- MiniMed 670G Insulin Pump (MMT-1760, MMT-1761, MMT-1762, MMT-1780, MMT-1781, MMT-1782)Open, Classified
Z-1739-2026 · Started Feb 13, 2026 · Posted by FDA Apr 2, 2026
Reason given: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and...
Cause as FDA categorized it: Device Design · Device type: Automated Insulin Dosing Device System, Single Hormonal Control (OZP)
- MiniMed 770G Insulin Pump (MMT-1880, MMT-1881, MMT-1882, MMT-1890, MMT-1891, MMT-1892)Open, Classified
Z-1742-2026 · Started Feb 13, 2026 · Posted by FDA Apr 2, 2026
Reason given: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and...
Cause as FDA categorized it: Device Design · Device type: Automated Insulin Dosing Device System, Single Hormonal Control (OZP)
11 more recall records with a free account
Published research
The most relevant PubMed records for "MiniMed 770G"[tiab]. The summary above synthesizes these.
- Effects of hybrid closed-loop system on glycemic control and psychological aspects in persons with typeߙ1 diabetes treated with sensor-augmented pump: A prospective single-center observational study.
Akiyama T, Yamakawa T, Orime K, et al. · J Diabetes Investig · 2024Observational Study
- Effects of switching from MiniMedࡊ 640G to 770G on continuous glucose monitoring metrics and DTR-QOL scores: An observational study of Japanese people with type 1 diabetes mellitus.
Kogai T, Sato J, Yasuda H, et al. · J Diabetes Investig · 2025Observational Study
- A heuristics matrix for evaluating the learnability of safety critical medical systems.
Turner J, Bowen J, Moxham-Bettridge V · Comput Struct Biotechnol J · 2025
- Advances in insulin pump systems lead to stepwise improvements in treatment satisfaction in people with type 1 diabetes: A single-center retrospective study.
Shimizu N, Ishimoto N, Sakamoto U, et al. · J Diabetes Investig · 2026
- Improving glycemic control by transitioning from the MiniMedTM 640G to 770G in Japanese adults with type 1 diabetes mellitus: a prospective, single-center, observational study.
Kubota S, Sato A, Hosokawa M, et al. · Endocr J · 2024Observational Study
- Impact of system updates for sensor-augmented pump therapy on glycemic management in Japanese individuals with type 1 diabetes (SAP-J T1D study).
Saito S, Yamamoto A, Miyazaki Y, et al. · J Diabetes Investig · 2026Observational Study
- Safety Event Outcomes and Glycemic Control with a Hybrid Closed-Loop System Used by Chinese Adolescents and Adults with Type 1 Diabetes Mellitus.
Pei Y, Ke W, Lu J, et al. · Diabetes Technol Ther · 2023Clinical Trial
- Glycemic variability and quality of life outcomes after changing to hybrid closed-loop system in Japanese individuals with type 1 diabetes using a conventional predictive low-glucose suspended insulin pump system.
Fuchigami A, Kojimahara Y, Yoshikawa F, et al. · Diabetol Int · 2025
- Efficacy of MiniMedࡊ 780G® on glucose management, sleep quality, and psychological aspects in persons with type 1 diabetes treated with MiniMedࡊ 770G®: A 3-month prospective single-center observational study.
Akiyama T, Orime K, Akamatsu R, et al. · J Diabetes Investig · 2026Observational Study
- Effects of switching from MiniMedࡊ 770G to 780G on continuous glucose monitoring metrics and DTR-QOL scores: An observational study of Japanese people with type 1 diabetes mellitus.
Takagi E, Sato J, Ayame T, et al. · J Diabetes Investig · 2026Observational Study
- Case of type 1 diabetes mellitus with decreased hemoglobin glycation index after switching insulin pump.
Hasegawa M, Katayama A, Morimoto E, et al. · J Diabetes Investig · 2025Case Reports
- Early Real-World Performance of the MiniMedࡊ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States.
Thrasher JR, Arrieta A, Niu F, et al. · Diabetes Technol Ther · 2024
Other devices of this type
Also filed under product code OZP.
- MiniMed 670G SystemMedtronic Minimed, Inc. · PMA 2025
- MiniMed 780G SystemMedtronic Minimed, Inc. · PMA 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.